Dyne Therapeutics Unveils Promising DYNE-251 Data for Duchenne Muscular Dystrophy

Dyne Therapeutics, Inc. (Nasdaq: DYN) has announced encouraging long-term clinical results from its Phase 1/2 DELIVER trial, revealing that DYNE-251 delivers sustained functional improvement for individuals with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. The data, presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, underscores the potential of DYNE-251 to address the significant unmet medical need in DMD, a progressive and life-threatening neuromuscular disorder. With a well-established regulatory pathway utilizing dystrophin expression as a surrogate endpoint, Dyne is targeting U.S. accelerated approval in early 2026.

John Cox, Dyne’s CEO, emphasized the breakthrough nature of these results, highlighting DYNE-251’s potential for durable and redosable treatment. Experts in the field, including Kevin Flanigan, M.D., noted that the dystrophin expression induced by DYNE-251 surpasses previous exon 51 skipping agents, with strong indications of clinical efficacy. Updated functional data from the DELIVER trial showed sustained improvement over 12 months in patients receiving the registrational dose, while safety data as of February 7, 2025, continue to support a favorable profile. If approved, DYNE-251 could provide a transformative option for both newly diagnosed and currently treated DMD patients.